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ABSTRACT  The  biosynthesis  of  von  Willebrand  protein  by  human  endothelial  cells  was 
impaired  by the  presence  of the  carboxylic  ionophore  monensin.  Several  processing  steps 
that have  been localized to the Golgi apparatus were affected  in a dose-dependent  manner, 
including  carbohydrate  processing,  dimer  multimerization,  and  precursor  cleavage.  Since 
multimerization was more susceptible to the ionophore than was precursor cleavage, it appears 
that these processing steps are separate  events.  As expected, dimer formation, which occurs 
in the rough endoplasmic reticulum, was unaffected by monensin. Thus, at high concentrations 
of monensin, only dimer molecules were produced and secreted. The observed inhibition of 
multimer formation and precursor cleavage  were not likely the result of incomplete carbohy- 
drate processing,  since inhibition  of complex carbohydrate formation  by swainsonine did not 
interfere with the other processing steps. Monensin also affected the capacity of endothelial 
cells  to  store  von  Willebrand  protein,  as  the  ratio  of  secreted  to  cell-associated  protein 
increased dramatically  in the presence of monensin,  and the  processed  forms could  not be 
found  in the treated cells. The low molecular weight multimers produced  in the presence of 
monensin  did not incorporate  in the endothelial cells' extracellular  matrix nor did they bind 
to the matrix of human foreskin fibroblasts.  In summary, the presence of monensin in human 
endothelial cell culture produced experimental conditions that mimic Type IIA von Willebrand 
disease,  in that the cells synthesized and secreted only low molecular weight von Willebrand 
protein multimers, which were functionally defective. 
von Willebrand (vW)' protein is a large adhesive glycoprotein 
involved  in  the  binding  of platelets  to  exposed  basement 
membranes during vascular injury (1,  2,  3).  vW protein  is 
present in the basement membrane (4) and in the platelet a- 
granules (5, 6) from which it is secreted after platelet activa- 
tion. vW protein is synthesized by megakaryocytes (7, 8) and 
by endothelial cells (9). Endothelial cells store vW protein in 
endothelial ceU-specific organelles called Weibel-Palade bod- 
ies (10) and incorporate it into their extraceUular matrix, vW 
protein subunit is first synthesized as a precursor polypeptide 
chain  of 260,000-mol-wt  (11,  12), which  dimerizes in  the 
endoplasmic reticulum. After transport of the dimers to the 
Abbreviation used in this paper: vW, von Willebmnd (protein). 
Golgi apparatus, the carbohydrates are processed from high 
mannose to complex type, accompanied by an apparent in- 
crease in size of the subunits to 275,000-mol-wt. The dimers 
then form large multimers by disulfide bond formation and 
in parallel, the prosequence is cleaved to generate the final 
220,000-mol-wt vW protein subunit (13). Most of the secreted 
vW protein consists of a 220,000-mol-wt subunit, but a small 
amount of the 275,000-mol-wt subunit precursor is also se- 
creted (11). 
In Type IIA vW disease, large and intermediate vW protein 
multimers are absent (14). The bleeding time of these patients 
is prolonged because the  small  multimers do  not  support 
efficient attachment  of platelets  to  the  vascular basement 
membrane (15). We were interested in whether experimental 
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molecular weight multimers in tissue culture by inhibiting the 
interdimer  disulfide  bond  formation.  This  processing  step 
occurs in the Golgi apparatus (13) and possibly continues in 
Weibel-Palade bodies, and electron microscope observations 
suggest  that  Weibel-Palade  bodies originate  from the Golgi 
apparatus (16).  The carboxylic ionophore monensin, which 
causes equilibration of the monovalent ions Na  ÷, K ÷, and H + 
(17), has been shown to primarily affect the Golgi apparatus 
(18)  and to inhibit the protein processing steps localized to 
this organelle (19). We have observed that monensin inhibits 
carbohydrate processing of vW protein from the high man- 
nose to the complex type (13).  We now report the effect of 
monensin on other steps in the biosynthesis of vW protein, 
in  particular, multimer formation, and examine  how struc- 
tural defects affect the ability ofvW protein to be incorporated 
into the extracellular matrix. 
MATERIALS  AND  METHODS 
Cells and  Culture  Conditions:  Endothelial  cells  were  obtained 
from human umbilical vein by mild proteolytic digestion as described previ- 
ously ( 10, 20). Cells were cultured in McCoy's 5A medium (Flow Laboratories, 
inc.,  McLean,  VA)  containing  20%  fetal bovine  serum.  Human  foreskin 
fibroblasts in sixth passage, a gift from S. Schmidt (University of Rochester), 
were grown in the same medium. Monensin was obtained  from Calbiochem- 
Behring Corp. (La Jolla, CA), and swainsonine was a kind gift from Drs. R. G. 
Arumugham and M. L. Tanzer (University of  Connecticut  Health Center). The 
drugs  were dissolved in ethanol,  and very small amounts of stock solutions 
were added to culture  medium; control  cells were treated with ethanol  alone. 
Ethanol  improved  monensin solubility in comparison to our earlier study in 
which the drug was suspended in water (13). For continuous metabolic labeling, 
cells were grown in the presence of [35S]methionine  (25 t~Ci/ml, 18.7 Ci/mmol, 
Amersham Corp., Arlington Heights, IL). 
Antisera:  Preparation  and characterization  of antisera  against  human 
vW protein  were as described  previously  (10, 21). Some experiments  used 
antiserum purchased from Calbiochem-Behring Corp. Monospecific antifibro- 
nectin antiserum was a kind gift from Dr. R. O. Hynes (Massachusetts Institute 
of Technology) (22). 
Pulse-Chase Experiments in the Presence of Monensin:  All 
media  contained  1 ~M monensin,  and incubations  were at 37"C. Cells were 
preincubated  for 45 min in medium containing  fetal bovine serum and for 15 
min in serum-free  medium. Medium  was then removed  and the cells were 
covered with 1 ml serum-free medium containing  1.5 mCi [3SS]methionine for 
20 rain. Cells were then rinsed in medium containing serum and incubated in 
this medium for varying lengths of time. Control cells were treated identically 
but without monensin. 
Purification  of vW Protein:  vW  protein  was immunopurified  as 
described  previously (13), and samples were analyzed  by gel electrophoresis 
after the radioactive count was determined. 
Endoglycosidase  H Digestion:  The enzyme was a generous gift of 
Dr. P. W. Robbins (Massachusetts Institute  of Technology) and was purified 
according to Tarentino et al. (23). Purified vW protein  was diluted  in 0.1  M 
Tris  buffer,  pH  5.8, so  that  the  final  concentration  of SDS  was  <0.5%. 
Endoglycosidase H was added (3 ug/ml), and samples were incubated  for 2 h 
at 37"C before analysis on gels. 
Electrophoresis  Gels:  SDS  polyacrylamide  gels were  prepared  as 
described  by  Laemmli  (24),  and agarose horizontal  slab gels were prepared 
using a solution  of 2% agarose, 0.1% SDS in @05 M phosphate  buffer at pH 
7.0. Two-dimensional gel electrophoresis was performed as described previously 
(13). 
Readdition  of Purified vW Protein to Monensin-treated En- 
dothelial Cells:  Cells  freshly obtained from umbilical vein were plated at 
high density on glass coverslips and after 2 d, the medium was exchanged for 
medium containing  10  -8 M monensin. Ceils were grown in this medium for 4 
d  (with  one medium exchange), during  which  time they  started  to develop 
extracellular matrix. At the end of the 4-d period, purified plasma vW protein 
was added to some coverslips (final concentration  of 20 ~g/ml) in the presence 
of monensin for an additional  overnight incubation.  The remaining coverslips 
were  incubated  in  the  absence  of exogenous  vW protein.  The purified  vW 
protein was a side product from a preparation of factor VIII (25) and was a gift 
from M.  Anderson (University of Rochester).  Similar results  were obtained 
when endothelial cells treated  with monensin were overlayed  with 3-d-old 
culture medium containing vW protein obtained from untreated  cells.  This 
overlay was performed in the presence  of monensin. Coverslips  were then 
washed and processed for fluorescence  microscopy. 
Swainsonine Treatment of Cells for Fluorescence Micros- 
copy:  Cells freshly  obtained from umbilical veins were plated  on glass 
coverslips and after 2 d, their medium was exchanged for medium containing 
1 ug/ml swainsonine. The cells were grown in this medium for 5 d (with one 
medium change) before being processed for fluorescence  microscopy. 
Immunofluorescence  staining was performed as described previously (10). 
RESULTS 
Effect of Monensin on the Polymeric Structure  of 
vW Protein 
Human umbilical vein endothelial cells were metabolically 
labeled with [35S]methionine in the presence of varying con- 
centrations of monensin. After 3 d, vW protein was purified 
from the culture medium and cell  lysate and was analyzed 
nonreduced on 2%  agarose gels (Fig.  1). There was a  dose- 
dependent decrease in size of secreted (Medium) high molec- 
ular weight (HMW) multimers, with accumulation of the low 
molecular weight species. Low concentrations of monensin (1 
x  10  -s  M)  produced  broader bands  than  that  seen  in  the 
absence of monensin (Fig.  1).  Two-dimensional gel  electro- 
phoresis of these samples with reduction in the second dimen- 
sion (not shown) revealed that this heterogeneity was due to 
a  greater  proportion  of precursor  subunits  in  these  small 
polymers. This was in contrast with untreated cultures which 
contained  only  a  small  amount  of vW  protein  precursor 
subunit in the multimers (13). 
When the concentration of monensin was increased to 125 
x  10  -s M, only the vW protein dimer was secreted (Fig.  1). 
Higher monensin concentrations caused a  large decrease in 
protein synthesis, but to the extent that vW protein was still 
produced, it was in dimer form and monomer secretion did 
not  occur.  Thus,  interdimer  disulfide  bond  formation was 
FIGUre  I  The effect of monensin on multimerization of vW  pro- 
tein.  Human  umbilical  vein  endothelial  cells  were  metabolically 
labeled for 3 d in the presence of monensin, after which vW protein 
was  purified  from  the  medium  and  the  cell  lysate  (Cells). The 
nonreduced vW protein was electrophoresed on 2% agarose gels, 
autoradiographs of which are shown in this figure. Monensin limited 
the size of multimers in a dose-dependent manner by inhibition of 
interdimer  disulfide  bond  formation.  Only  dimer  molecules  re- 
mained in the cell  lysate, while the other multimers produced in 
the presence of monensin were preferentially secreted. 
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formation was unaffected. In four independent experiments, 
we have determined the total number of secreted multimer 
bands from overexposed autoradiographs  of gels  similar to 
that presented in  Fig.  1. This showed that the formation of 
more  than  half of the  multimer  species  was  inhibited  by 
concentrations of monensin as low as 10  -8 M, whereas a dose 
of monensin two orders of magnitude larger was needed to 
inhibit  formation of tetramers (Table I).  Preincubation  for 
several hours with the  same concentration  of monensin as 
used during the metabolic labeling produced the same results. 
Cellular vW protein from monensin-treated cultures (Cells) 
showed the absence of all polymers larger than dimer (Fig.  l), 
indicating that the smaller polymers produced in the presence 
of monensin were preferentially secreted rather than stored in 
the cells. 
Pulse-chase experiments confirmed the insensitivity of the 
dimerization step to monensin (Fig.  2).  The time course of 
formation of dimers from the 260-kD precursor was identical 
in  both  control  and  monensin-treated cultures.  Up  to  2  h 
from the onset of labeling, when the protein is still mainly in 
the  endoplasmic reticulum  (13),  the  monensin-treated and 
control samples were indistinguishable by gel electrophoresis. 
Only  later when  multimerization  occurred  in  control  cells 
was a difference observed; this process did not take place in 
monensin-treated cultures (Fig.  2).  The formation of fibro- 
nectin dimer was also unaffected by monensin treatment of 
the endothelial cells (data not shown). 
In all of the pulse-chase experiments, there was an initial 
delay  in  secretion  of vW  protein  in  the  monensin-treated 
cultures. Quantitation of secreted vW protein from two ex- 
periments showed that  2.3  times more vW protein was se- 
creted in the control cultures than was secreted in monensin- 
treated cultures during the first 2 h of chase (Fig. 2). However, 
this ratio decreased to 0.75  by 6  h  of chase,  reflecting the 
higher secretion  of vW protein  in  longer monensin-treated 
cultures. 
Effect of Monensin  on Precursor Cleavage, 
Carbohydrate  Processing, and Intracellular 
Storage of vW Protein 
To examine the composition and subunit size ofvW protein 
synthesized in the presence of increasing doses of monensin, 
the purified protein was analyzed reduced on 5% polyacryl- 
amide gels (Fig. 3). Secreted vW protein (Medium) showed a 
gradual increase in precursor subunit content, relative to the 
amount of cleaved subunit.  Inhibition of precursor cleavage 
by monensin was quantitated by scanning several exposures 
of autoradiographs from three independent experiments (Ta- 
ble I). The precursor cleavage processing step appeared to be 
less susceptible to monensin than was vW protein multimer- 
ization.  While  10  -8  M  monensin  decreased  the  observed 
number  of multimer bands  from  more than  14  to  6,  the 
precursor cleavage was inhibited only 18 %. Also, at the highest 
monensin dose (125  x  10  -8 M), when multimerization past 
dimer was completely inhibited, residual cleavage of  precursor 
subunit occurred (Table I). 
Both secreted subunits (275,000-mol-wt and 220,000-mol- 
wt) obtained from cultures exposed to increasing concentra- 
tions of monensin migrated progressively faster on the poly- 
acrylamide gels (Fig. 3). This effect probably was the result of 
increasing  monensin  inhibition  of conversion  of the  high 
mannose carbohydrate to the  complex type. This was sup- 
ported by the following observations: (a) secreted vW protein 
synthesized in the presence of high doses of monensin (i.e.,  1 
gM) was endoglycosidase H-sensitive (13),  and (b) secreted 
vW protein from cells exposed to low doses of monensin did 
TABLE  I.  Effect  of Monensin  on Polymeric Structure and Subunit Composition  of Secreted vW Protein 
Monensin concentration (10  -8 M) 
0  1  5  25  125 
Number of multimer bands*  >14  6  5  3  1 
220,000-mol-wt subunit (% total)*  98.7 (0.3)  81.1  (4.7)  50.8 (3.3)  30.6 (1.4)  21.6 (3.3) 
* Average number of multimer bands recorded from four experiments such as that shown in  Fig. 1. 
* Percentage  of 220,000-mol-wt subunit measured by densitometric scan o(autoradiographs of three experiments similar  to that shown in Fig. 3. Values shown 
in parenthesis  indicate standard error of mean. 
FIGURE  2  Pulse-chase  experi- 
ment.  Endothelial  ceils  were  la- 
beled for 20 min with [3SS]metbi- 
onine and then  incubated  in  un- 
labeled medium  in  the  presence 
(+)  or absence  (-)  of  1 /~M  mo- 
nensin.  Numbers  indicate  the 
elapsed  time  in  hours  from  the 
onset of labeling, vW protein pu- 
rification  and  analysis  was  as  in 
Fig.  1.  Monensin  entirely  inhib- 
ited  multimer  formation,  but  di- 
merization  was  unaffected.  Also 
note  the  higher  amount  of  vW 
protein  secreted  in  the  control 
cultures  in  comparison  with  the 
monensin-treated  culture  at  the 
2-h time point. 
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endoglycosidase H-resistant (not shown). 
Examination of reduced cellular vW protein (Cells)  (Fig. 
3) showed that even the lowest doses of monensin removed 
the majority of the 220,000-mol-wt processed subunit from 
the cells. The prominent subunit remaining in the ceils was 
the 260,000-mol-wt precursor. The absence of the 220,000- 
mol-wt  subunit  resembled  the  absence  of low  molecular 
weight polymers from cells grown in the presence of  monensin 
(Fig.  l). These observations are in agreement with the loss of 
Weibel-Palade  bodies  from  monensin-treated  endothelial 
cells,  as shown by immunofluorescence staining with anti- 
vW protein antiserum and by electron microscopy (26;  our 
unpublished observations). 
The effect of monensin on synthesis, secretion, and pro- 
portion of secreted to cell-associated  vW protein was quanti- 
rated in three experiments, using metabolically labeled cul- 
tures after monensin treatment for 3 d (Table II). The lowest 
concentration of monensin stimulated vW protein synthesis 
slightly.  Higher concentrations had  an  apparent inhibitory 
effect (Table II, A), but it is also possible that this decrease in 
total vW protein was due to enhanced destruction of newly 
made molecules. Monensin dramatically affected the secreted 
to cell-associated  ratio of vW protein. All concentrations of 
monensin that were tested produced more than a threefold 
increase in this ratio (Table II, B), reflecting the low amount 
of processed vW protein remaining in the cell lysate and the 
absence of  the vW protein storage compartment--the Weibel- 
Palade bodies. 
Effect of Swainsonine on vW Protein Biosynthesis 
The polymerization defect and the incomplete propeptide 
cleavage in monensin-treated cells could possibly be the con- 
sequence of improper carbohydrate processing.  To examine 
the importance of complex type carbohydrate on the biosyn- 
thesis of vW  protein, cells  were grown in  the  presence of 
swainsonine, which inhibits the Golgi enzyme mannosidase 
II  (27),  thereby preventing the  full  formation of complex 
carbohydrate. The carbohydrates produced in the presence of 
swainsonine are of  a hybrid type that is susceptible to digestion 
by the enzyme endoglycosidase H  (28,  29), while complex 
carbohydrates are resistant to this enzyme. The results showed 
that vW protein synthesized in the presence of 1 ug/ml of 
swainsonine was susceptible to endoglycosidase H  digestion 
and therefore had incompletely processed carbohydrate (Fig. 
4a). The ratio of precursor (260,000 or 275,000-mol-wt) to 
the 220,000-mol-wt cleaved subunit from the swainsonine- 
treated cells was unchanged (Fig. 4a), as was the polymeric 
structure of the nonreduced vW protein, in comparison with 
protein from untreated controls (Fig. 4  b). It is likely, there- 
fore, that the presence of incompletely formed carbohydrate 
on  vW protein  molecules did  not  affect the  ability of the 
protein to undergo proper biosynthetic processing that yields 
multimers of the 220,000-mol-wt subunit. 
FIGURE  3  Effect of monensin on the cleavage of vW  protein pre- 
cursor,  vW  protein was purified  from  metabolically labeled endo- 
thelial  cells  and  medium  as  described  in  Fig.  I  and  analyzed 
reduced on 5% polyacrylamide gels. Monensin increased the ratio 
of precursor  (275 or 260)  to the cleaved subunit  (220)  in a  dose- 
dependent manner. The migration of the secreted 275,000-mol-wt 
and  the  220,000-mol-wt  subunits  increased  progressively  with 
higher concentrations of monensin,  probably as the result of inhi- 
bition of carbohydrate processing. In addition, the 220,000-mol-wt 
subunit was preferentially secreted in the presence of monensin as 
it was absent from the cell lysates. The minor band migrating faster 
than the  220,000-mol-wt  subunit  (Medium)  appears to  be a  frag- 
ment of vW  protein which we observe often in long-term labeled 
cultures. 
Effect of Monensin and Swainsonine on vW 
Protein Participation in the Extracellular Matrix 
In patients with Type IIA vW disease,  only low molecular 
weight  multimers of the  protein circulate (30).  A  possible 
biological defect that could explain this disease  state would 
be a decreased or absent interaction of these low molecular 
weight  polymers with  the  matrix  of basement  membrane. 
Therefore, we examined the participation of the low molecu- 
lar weight vW protein produced in the presence of monensin 
in  the extracellular matrix of endothelial cells.  Endothelial 
cells were cultured on coverslips in the presence of different 
concentrations of monensin for several days. In parallel,  cells 
grown in  identical concentrations of monensin were meta- 
bolically labeled to examine the extent of multimerization of 
secreted  vW  protein  (Table  I).  While  cells  grown  in  the 
TABLE 11.  The Effect of Monensin on vW Protein Synthesis,  Storage,  and Secretion 
Monensin concentration (10  -8 M) 
0  1  5  25  125 
A.  Total vW protein* 
B.  Secreted/cell-associated vW protein 
C.  Secreted vW  protein* 
I  1.3  (0.2)  0.8 (0.2)  0.5 (0.1)  0,4 (0.1) 
1.5 (0.3)  4.8 (0.2)  5.2 (0.6)  4.5 (0.8)  5.0 (0.5) 
1  1.8 (0.1)  1.2 (0.2)  0.6 (0.1)  0.6 (0.1) 
* Values were normalized to those obtained for untreated controls; numbers in parenthesis indicate standard error of mean. 
WAGNER ET AL,  Monensin  Inhibits Polymerizatlon of vW Protein  1 1 5 FIGURIE 4  Effect  of swainsonine on carbohydrate processing, precursor cleavage, and polymerization  of vW protein. Endothelial 
cells were metabolically labeled for 2 d in the presence (+) or absence (-) of 1 #g/ml of swainsonine, vW protein was purified 
and analyzed reduced on a 5% polyacrylamide gel (a) and nonreduced on a 2% agarose gel (b), autoradiographs of which are 
shown here.  Swainsonine  did  not affect  the  ratio of precursor  (275 or 260)  to the cleaved subunit (220)  but  it did affect 
endoglycosidase  H sensitivity (lane E) of the protein (a). While only the 260,000-mol-wt intracellular precursor of control cultures 
was endoglycosidase H-sensitive, the 275,000-mol-wt and 220,000-mol-wt subunits of swainsonine-treated  cultures were also 
susceptible  to endoglycosidase  H. This was shown by a shift in migration of the digested protein (a). The multimeric pattern of 
cellular and secreted vW protein from control and swainsonine-treated  cultures were very similar (b). 
absence of monensin developed a  normal vW protein-con- 
taining matrix as seen by immunofluorescence staining (Fig. 
5a),  cells treated with  10  -s M  or higher concentrations of 
monensin did not incorporate vW protein into their matrix 
(Fig. 5 c). Staining with anti-fibronectin antibody showed that 
monensin had a concentration-dependent inhibitory effect on 
the  production  of fibronectin  matrix,  although  it  was  still 
prominent at the  10  -8 M  monensin concentration (compare 
Fig. 5 b and 5 d). 
To test whether the  matrix produced  in  the  presence of 
monensin could bind vW protein, purified plasma vW was 
added (20 tzg/ml final concentration) overnight to cells grown 
in monensin-containing medium for 4 d. Although the matrix 
staining produced by the exogenous plasma vW protein was 
somewhat fainter than  that  seen in  untreated  cultures,  the 
ability of the matrix to bind vW protein was clearly demon- 
strated (Fig.  5, e and f). The lack of binding of vW protein 
synthesized in  the  presence of monensin was not due  to  a 
decreased secretion of this protein,  since  more vW protein 
was secreted with low concentrations of monensin (Table II, 
C). We have also tested the ability of secreted vW protein in 
the monensin-treated cultures to bind to the normal extracel- 
lular  matrix  of human  foreskin  fibroblasts  which  do  not 
synthesize vW protein. Culture media produced in the pres- 
ence or absence of 10  -8  M  monensin were incubated with 
human  foreskin  fibroblast cultures  for 2  d  after which  the 
cells were fixed and stained with anti-vW protein antiserum 
(Fig.  6).  Only vW protein from the medium of cells grown 
without monensin bound to the extracellular matrix of the 
fibroblasts. Adding monensin to the medium did not affect 
the binding. It appears therefore that the vW protein lacking 
the high molecular weight multimers that is produced in the 
presence of monensin cannot participate in  the endothelial 
cell extracellular matrix nor can it bind to foreign matrices. 
The defective matrix-binding of vW protein produced in 
the presence of monensin could possibly be due to the absence 
of complex type carbohydrate on the molecules rather than 
to the lack of high molecular weight multimers. Endothelial 
cells  grown  for  5  d  in  the  presence of swainsonine  before 
staining with anti-vW protein antiserum had normal Weibel- 
Palade bodies and a normal vW protein extracellular matrix 
(Fig. 7). Therefore, the absence of complex type carbohydrate 
did not affect the storage of vW protein in the Weibel-Palade 
bodies  or  the  participation  of secreted  vW  protein  in  the 
extracellular matrix. 
DISCUSSION 
Effect of Monensin on vW Protein Production, 
Storage, and Secretion 
The impact monensin  had  on  vW protein  synthesis was 
dependent  upon the monensin concentration  (Table II, A). 
At all concentrations used in our study (1-125  x  10  -8 M), 
monensin favored secretion of vW protein, in the sense that 
a greater proportion of synthesized vW protein was released 
into  the  culture  medium  (Table  II,  B).  This  increase  in 
exocytosis of vW protein was perhaps due to an increase in 
the  availability  of intracellular  Ca  2÷,  caused  indirectly  by 
monensin, as was observed for catecholamine secretion from 
secretory granules (31).  On the other hand, a  very high dose 
1 16  THE  JOURNAL OF  CELL BIOLOGY • VOLUME  101,  1985 FIGURE  5  Effect of monensin on vW protein incorporation into endothelial cell extracellular matrix. Immunofluorescent staining 
with anti-vW protein antiserum (a, c, e, and f) or antifibronectin antiserum (b and d) of permeabilized 1-wk-old human umbilical 
vein endothelial cell cultures. Cells grown in the absence of monensin developed a prominent matrix that was positive for vW 
protein (a) and fibronectin (b).  Weibel-Palade bodies containing vW  protein are indicated by the arrowhead in a. While the 
presence of  10  -8 M  monensin reduced the amount of fibronectin-containing matrix filaments present in  the culture (d),  the 
participation of vW protein in the matrix was completely abolished (c). Intracellular protein distribution was also different, as no 
structures resembling WeibeI-Palade bodies were present (c and f). As observed by others (references  26 and 41), intracellular 
accumulation of fibronectin occurred in the presence of monensin (arrowhead, d). The addition of 20 #g/ml of purified plasma 
vW protein to the monesin-treated culture, in the presence of added monensin, resulted in staining of the matrix with anti-vW 
protein antiserum (e). Panel f shows a higher magnification of this matrix decoration of monensin-treated cells with exogenous 
vW protein. Bars: a-e, 20/~m; f, 10 p.m. 
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fibroblasts. Fibroblasts  grown on  glass coverslips were overlayed 
with 3-d-old culture medium from endothelial cells grown in the 
absence (a) or presence (b) of  10  -8 M  monensin. After 2  d, the 
fibroblasts were fixed, permeabilized,  and stained by immunofluo- 
rescence with anti-vW protein antiserum, vW protein produced in 
the presence of monensin did not bind to the fibroblast extracellular 
matrix. Bar, 20/~m. 
of monensin (10  -s M) inhibited vW protein secretion entirely 
(26).  The secretion of human chorionic gonadotropin is also 
affected differently at different concentrations of monensin. 
Peters et al. reported that monensin at 5 x  10  -7 M inhibited 
carbohydrate processing of the hormone without significantly 
affecting secretion,  while  10-fold  more monensin  inhibited 
secretion drastically (32). Considering these observations and 
our results, it appears to be advantageous to study the effect 
of monensin on protein processing and secretion at several 
different concentrations. 
Pulse-chase experiments have shown that  1 ~M monensin 
slightly increased the time required from synthesis to secretion 
of vW protein (Fig. 2). Similarly, monensin has been observed 
to decrease the rate of intracellular movement of procollagen 
and fibronectin (33) and other proteins (17). It is unlikely that 
the longer time required for transport of vW protein in the 
presence of monensin is due to its accumulation in a  post- 
Golgi compartment because there was no cellular accumula- 
tion  of low molecular weight multimers in  the presence of 
monensin.  These  multimers  appeared  to  be  preferentially 
secreted and were not easily detected in the cells (Fig.  1). 
One  of the  major consequences  of monensin  treatment, 
even at concentrations as low as  10  -8 M, was the disappear- 
ance of Weibel-Palade bodies (26;  Fig.  5).  The data do not 
allow  us  to  determine  whether  new  Weibel-Palade  bodies 
could  not  be  produced  by the  Golgi apparatus  or  if their 
possible recycling was inhibited by monensin. In either case, 
vW protein could not be stored in the endothelial cells and 
the ratio of secreted to cell-associated vW protein increased 
dramatically (Table II, B). Furthermore, the more processed 
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FIGURE  7  Effect  of  swainsonine on  vW  protein  distribution  in 
endothelial cells.  Human umbilical vein endothelial cells cultured 
in the absence (a) or the presence (b) of I  #glml swainsonine were 
permeabilized and stained with anti-vW  protein antiserum. The 
distribution of vW  protein in the treated and  untreated cultures 
was very similar. Note the presence of Weibel-Palade bodies (ar- 
rowheads) and matrix filaments in both a and b. Bar, 20 #m. 
forms of vW  protein  produced  in  the  presence  of a  low 
concentration  of monensin,  i.e.,  multimers  larger  than  a 
dimer which  contain  the  220,000-mol-wt  cleaved subunit, 
were found only in the secreted fraction (Figs.  1 and 3). The 
depletion of all vW protein forms except the 260,000-mol-wt 
dimers  in  monensin-treated  cells  again  indicates  that  this 
dirtier was present in  a  monensin-insensitive compartment 
and was not stored in the Weibel-Palade bodies. 
Inhibition by Monensin of the Processing Steps 
Localized in the Golgi Apparatus and the 
WeibeI-Palade Bodies 
The presence of the carboxylic ionophore monensin had 
an inhibitory effect on the  biosynthetic processing steps of 
vW protein that have been assigned to the Golgi apparatus 
and the  Weibel-Palade bodies.  Earlier processing steps that 
occur  in  the  rough  endoplasmic  reticulum  (13)  were  not 
inhibited by the presence of the ionophore. Monensin inhib- 
ited both multimerization and precursor cleavage in a dose- 
dependent manner (Table I). Although we did not examine 
directly the extent of carbohydrate processing as a  function 
of monensin concentration, it is likely that it also varied with 
the  monensin  dose,  inasmuch  as  the  size  of the  secreted 
subunits decreased gradually with increasing concentrations 
of monensin (Fig. 3). Pulse-chase experiments have shown that multimerization 
and precursor cleavage occur at about the same time (13), but 
the susceptibility of these two processing steps to monensin 
was very different (Table I). This disparity argues in favor of 
the two processing steps being separate enzymatic events. The 
interdimer disulfide bond formation in vW protein is the first 
example described of disulfide bond formation occurring in 
the Golgi apparatus where it can be inhibited by monensin. 
It is likely that vW is not unique in this respect and that other 
proteins form interchain disulfide bonds in the Golgi appa- 
ratus. It appears that this Golgi-localized multimerization step 
requires special conditions,  for example, low pH (34),  and 
likely a  specific enzyme, and therefore it would not be ex- 
pected to occur spontaneously after the protein was secreted 
(Fig.  1).  It is also unlikely that an equilibrium between the 
different polymeric sizes could exist outside the cell. 
The inhibition  of polymerization and precursor cleavage 
did not appear to be consequences of the absence of carbo- 
hydrate processing in the presence of monensin.  To begin, 
vW protein synthesized by cells cultured in the presence of a 
very low concentration of monensin lacked the highest mo- 
lecular weight  multimers but  was still  endoglycosidase H- 
resistant  (not  shown).  Further,  swainsonine,  a  drug  which 
inhibits the Golgi enzyme mannosidase II (27) and therefore 
inhibits biosynthesis of complex type carbohydrate, did not 
affect  either  precursor  cleavage  or  high  molecular  weight 
multimer formation ofvW protein (Fig. 4). The carbohydrate 
processing was indeed inhibited in the presence of swainson- 
ine  as  could  be  demonstrated  by the  susceptibility  of the 
protein to the enzyme endoglycosidase H (Fig. 4a). 
At high concentrations of monensin, the major vW protein 
species secreted was the dimer of the 260,000-mol-wt subunits 
(Figs.  1 and 3). Since this species is normally present in the 
endoplasmic reticulum and  is not secreted (13),  monensin 
produced a functional or possibly physical bypass of the Golgi 
apparatus. This should be elucidated by a cell fractionation 
study. 
Low Molecular Weight Multimers Produced in 
the Presence of Monensin  Do Not Participate in 
the Extracellular Matrix 
vW protein mediates the binding of platelets to subendo- 
thelium,  an in  vitro model of which is the endothelial  cell 
extracellular  matrix,  vW protein  was  demonstrated  in  the 
matrix (Fig.  5 a) where it co-distributed with other compo- 
nents such as fibronectin and collagens (35,  36). Ceils grown 
in  l0  -8 M  monensin produced a decreased quantity of fibro- 
nectin-containing matrix, from which vW protein was com- 
pletely lacking, as determined by fluorescence staining (Fig. 
5 c). The matrix produced in the presence of monensin was 
still able to bind exogenous normal vW protein, from control 
cell  culture  medium  (not  shown)  or from  human  plasma 
(Fig.  5, e and f). vW protein synthesized and secreted in the 
presence of monensin also could not bind to the extracellular 
matrix  of human  foreskin  fibroblasts, whereas vW protein 
from untreated cultures did bind (Fig.  6).  The data strongly 
support the conclusion that the vW protein produced in the 
presence of monensin was functionally defective. It does not 
appear likely that the presence of <20% precursor subunit in 
the  dimer and  multimers was blocking the  binding  of the 
protein to the matrix, but we cannot rule out this possibility. 
We were more concerned about the possible role of complex 
type carbohydrate in the binding of vW protein to the extra- 
cellular matrix. This concern was suggested by observations 
of several patients with  a  variant  of vW disease who  had 
carbohydrate deficiency, in addition to other defects in vW 
protein  (37,  38).  However, endothelial  cells  grown  in  the 
presence of swainsonine produced vW protein with incom- 
pletely processed carbohydrates that remained endoglycosi- 
dase H-sensitive (Fig. 4a), but these cells had an apparently 
normal extracellular matrix containing vW protein (Fig.  7). 
Therefore, the defect in matrix participation of vW protein in 
the  presence of monensin  was  not  due  to  the  absence of 
complex type carbohydrate. 
The  major difference  between  vW  protein  produced  in 
control and  10  -s M  monensin-treated cultures that we have 
observed was the absence of large and medium-sized multi- 
mers in the monensin-treated cultures (Fig.  1; Table I). Type 
IIA vW disease has been attributed to the absence of these 
multimers. The importance of the large multimers may be 
explained if polyvalency was required for proper binding of 
the  protein  to  the  extracellular  matrix  or  in  vivo to  the 
basement membrane. For instance, sequences related to the 
known cell binding sequence of fibronectin (39) are present 
several times within each fibronectin subunit (40). 
The  addition  of monensin  to  endothelial  cell  cultures 
elicited changes in  synthesized vW protein that mimic the 
situation  existing in  Type IIA vW disease.  Thus,  the  high 
molecular weight multimers which are lacking in the human 
disease state were also missing from the endothelial cell cul- 
tures.  Furthermore,  the  monensin-treated cells  synthesized 
only low molecular weight multimers, similar in size to those 
found  in  Type  IIA  patients,  and  these  were  functionally 
defective, as is the  case  in  the  disease state.  As monensin 
inhibits posttranslational modifications localized to the Golgi 
apparatus, the data further indicate that a defect in the Golgi- 
controlled interdimer disulfide bond formation might be the 
pathogenetic mechanism underlying Type IIA vW disease. 
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